ARO-MAPT-SC Tau ASO Trial (NCT07221344)
Overview
flowchart TD
clinical_trials_aro_mapt_sc_ta["ARO-MAPT-SC Tau ASO Trial NCT07221344 - Arrowh"]
style clinical_trials_aro_mapt_sc_ta fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_aro__0["Trial Details"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__0
style clinical_trials_aro__0 fill:#81c784,stroke:#333,color:#000
clinical_trials_aro__1["Treatment Arms"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__1
style clinical_trials_aro__1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_aro__2["Mechanism of Action"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__2
style clinical_trials_aro__2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_aro__3["Antisense Oligonucleotide Technology"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__3
style clinical_trials_aro__3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_aro__4["Arrowheads Targeted RNAi Polymers TRiP"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__4
style clinical_trials_aro__4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_aro__5["Advantages Over Antibody Approaches"]
clinical_trials_aro_mapt_sc_ta -->|"includes"| clinical_trials_aro__5
style clinical_trials_aro__5 fill:#81c784,stroke:#333,color:#000
...ARO-MAPT-SC Tau ASO Trial (NCT07221344)
Overview
Mermaid diagram (expand to render)
ARO-MAPT-SC is an investigational antisense oligonucleotide (ASO) therapy developed by Arrowhead Pharmaceuticals designed to reduce production of microtubule-associated protein tau (MAPT) in early Alzheimer's disease. This Phase 1/2 trial (NCT07221344) represents a pioneering approach to neurodegenerative disease treatment by targeting tau at its source—the messenger RNA that encodes the tau protein—rather than targeting already-formed tau aggregates with antibodies["@schantz2023"].
The trial evaluates the safety, tolerability, and pharmacokinetics of ARO-MAPT-SC administered via intrathecal injection, marking one of the first clinical applications of RNA interference technology for Alzheimer's disease modification. If successful, this approach could establish a new therapeutic paradigm for tauopathies beyond traditional antibody-based approaches.
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT07221344 |
| Phase | Phase 1/2 |
| Status | Recruiting |
| Sponsor | Arrowhead Pharmaceuticals |
| Intervention | ARO-MAPT-SC (tau-targeted antisense oligonucleotide) |
| Estimated Enrollment | 60 participants |
| Study Start | June 2022 |
| Estimated Completion | December 2025 |
| Route | Intrathecal (lumbar puncture) |
| Study Design | Randomized, placebo-controlled, dose-escalation |
Treatment Arms
| Arm | Intervention | Dose | Randomization |
|-----|-------------|------|----------------|
| 1 | ARO-MAPT-SC | Low dose | 3:1 active:placebo |
| 2 | ARO-MAPT-SC | Medium dose | 3:1 active:placebo |
| 3 | ARO-MAPT-SC | High dose | 3:1 active:placebo |
| 4 | Placebo | N/A | 3:1 active:placebo |
The trial employs a single ascending dose (SAD) followed by multiple ascending dose (MAD) design to establish maximum tolerated dose.
Mechanism of Action
Antisense Oligonucleotide Technology
ARO-MAPT-SC utilizes RNA interference to selectively reduce tau production[@devos2017]:
ASO Mechanism:
Target binding: ASO binds complementarily to MAPT mRNA
RNase H recruitment: The RNA-DNA hybrid recruits RNase H enzyme
mRNA degradation: RNase H cleaves the mRNA strand
Translation block: Degraded mRNA cannot be translated into protein
Tau reduction: All tau isoforms (3R, 4R, and 2N) are reducedTargeted Approach:
- Direct targeting of tau at the production level
- Reduction of all tau isoforms simultaneously
- No effect on existing tau protein (cannot clear established tangles)
- Potential for disease modification if administered early enough
Arrowhead's Targeted RNAi Polymers (TRiP™)
Arrowhead Pharmaceuticals employs its proprietary TRiP™ delivery platform:
Platform Features:
- Conjugate chemistry: Enables tissue-specific delivery
- Enhanced uptake: Improved cellular entry vs. naked ASOs
- Reduced off-target: Tissue-selective delivery reduces side effects
- Sustained effect: Long duration of gene silencing after dosing
ARO-MAPT-SC Specifics:
- Target: MAPT mRNA in neuronal cells
- Delivery: Conjugate enables uptake across blood-brain barrier when delivered intrathecally
- Duration: Effects persist for months after single dose
Advantages Over Antibody Approaches
| Feature | Antibody Therapy | ASO Therapy (ARO-MAPT-SC) |
|---------|-----------------|---------------------------|
| Target | Extracellular tau | Intracellular tau mRNA |
| Mechanism | Tau clearance | Tau production reduction |
| Tau isoforms | Limited by epitope | All isoforms |
| Delivery | Peripheral injection | Intrathecal |
| Duration | Frequent dosing | Less frequent |
Scientific Rationale
Tau Pathology in Alzheimer's Disease
Tau protein plays a central role in Alzheimer's disease pathogenesis[@brundin2016]:
Tau Biology:
- Normal function: Stabilizes microtubules, supports axonal transport
- Hyperphosphorylation: Abnormal phosphorylation leads to aggregation
- NFT formation: Paired helical filaments accumulate as neurofibrillary tangles (NFTs)
- Spread: Pathologic tau propagates through neural networks
Clinical Correlation:
- Regional tau burden correlates with cognitive impairment
- NFT count at autopsy predicts ante-mortem dementia severity
- Tau accumulation precedes clinical symptoms
- Tau PET signal predicts future cognitive decline
Tau Reduction Rationale
Reducing tau production could provide disease-modifying benefits:
Theoretical Benefits:
- Prevent formation of new NFT pathology
- Slow or halt disease progression
- Potentially reverse cognitive decline if treatment begins early
- Address upstream cause rather than downstream effects
Preclinical Evidence:
- Tau reduction improves cognition in mouse models
- Tau ASOs reduce tau in brain and CSF of animal models
- Partial reduction sufficient for benefit (not complete elimination)
Study Design Details
Clinical Phase 1/2 Structure
The trial follows a structured development approach:
Single Ascending Dose (SAD) Phase
- Cohorts: 3 dose levels
- Participants: 8-12 per cohort
- Randomization: 3:1 active:placebo
- Duration: 12-week observation per cohort
- Endpoints: Safety, PK, CSF tau biomarkers
Multiple Ascending Dose (MAD) Phase
- Cohorts: 3 dose levels
- Participants: 10-15 per cohort
- Dosing: Monthly intrathecal administration
- Duration: 6-month treatment + 6-month follow-up
- Endpoints: Safety, efficacy endpoints
Eligibility Criteria
Inclusion Requirements
Age: 55-80 years
Diagnosis: Early Alzheimer's disease (MCI due to AD or mild AD dementia)
Cognitive status: MMSE 20-28
Amyloid positive: Confirmed via PET or CSF biomarkers (Aβ42, p-tau)
Stable medication: On stable AD medications for ≥30 days
Capacity: Able to provide informed consent with study partnerExclusion Criteria
Neurological: History of stroke, seizures, or other neurodegenerative disease
Psychiatric: Active major depression, psychosis
Medical: Contraindications to lumbar puncture
Prior therapy: Prior exposure to tau-targeted therapies
Imaging: Significant cerebrovascular disease on MRIClinical Procedures
Screening Procedures (Visit 1-2)
Comprehensive screening includes:
- Informed consent: Detailed explanation of procedures and risks
- Medical history: Complete neurological and psychiatric history
- Physical examination: Including vital signs and neurological exam
- Cognitive assessment: MMSE, CDR, ADAS-Cog13, FCSRT
- Brain MRI: Structural imaging to rule out other pathology
- PET imaging: Amyloid PET (if available)
- CSF collection: Lumbar puncture for biomarker analysis
- Laboratory tests: Blood chemistry, hematology, urinalysis
Dosing Procedures
Intrathecal Administration:
Participant positioned for lumbar puncture
CSF collected for baseline biomarkers (optional)
ARO-MAPT-SC or placebo administered
Post-injection monitoring (4-6 hours)
Assessment of injection siteSafety Monitoring:
- Vital signs (BP, HR, temperature)
- Neurological assessments
- Injection site inspection
- Adverse event collection
Follow-up Schedule
| Timepoint | Assessments |
|-----------|-------------|
| Week 1 | Safety call |
| Week 2 | PK/PD sampling |
| Week 4 | Cognitive testing, safety |
| Week 8 | CSF biomarkers (subset) |
| Week 12 | Full assessment |
| Month 6 | Safety and efficacy |
| Month 12 | Long-term follow-up |
Outcome Measures
Primary Endpoints
Safety and Tolerability
- Incidence of adverse events (AEs)
- Incidence of serious adverse events (SAEs)
- Assessment of injection site reactions
- Neurological examinations
Pharmacokinetics
- Plasma concentrations of ARO-MAPT-SC
- CSF concentrations (subset of participants)
- Population PK modeling
Secondary Endpoints
Target Engagement
- Change in CSF total tau
- Change in CSF phosphorylated tau (p-tau181)
- Correlation with dose level
Efficacy Signals
- Change from baseline in cognitive scales (ADAS-Cog13, MMSE)
- Clinical Dementia Rating (CDR) change
- Quality of life measures (QoL-AD)
Biomarker Assessments
- Amyloid PET change (subset)
- MRI volumetric measures
- Neurofilament light chain (NfL) in CSF
Exploratory Endpoints
- Tau PET imaging (optional substudy)
- Transcriptomic analysis of CSF cells
- Pharmacodynamic biomarkers
Clinical Development History
Preclinical Research
Key Preclinical Findings:
- Tau ASOs reduce brain tau in mouse models by >50%
- Reduction in tau protein in CSF of treated animals
- Improved cognitive performance in tau transgenic mice
- No significant off-target effects at therapeutic doses
Non-Clinical Toxicology
- Toxicology studies in rodents and non-human primates
- No significant safety concerns at projected therapeutic doses
-剂量-limited毒性 identified in chronic toxicology studies
- Supportive IND-enabling studies completed
Clinical Experience
ARO-MAPT-SC represents Arrowhead's neurological portfolio expansion:
Company's CNS Pipeline:
- CNS-directed ASO programs for various targets
- Established intrathecal delivery capabilities
- Track record with other CNS programs
Lessons from Other ASOs:
- Nusinersen (Spinraza) for spinal muscular atrophy
- Inotersen (Tegsedi) for hATTR polyneuropathy
- These programs established safety of intrathecal ASO delivery
Competitive Landscape
Tau-Targeting Strategies
| Approach | Agent | Company | Stage |
|----------|-------|---------|-------|
| ASO | ARO-MAPT-SC | Arrowhead | Phase 1/2 |
| Antibody | Semorinemab | Roche | Phase 2 |
| Antibody | Gosuranemab | Biogen | Phase 2 |
| Antibody | tilavonemab | AbbVie | Phase 2 |
| Vaccine | AADvac1 | Axon Neuroscience | Phase 2 |
| Small molecule | TRx0237 | TauRx | Phase 3 |
Positioning of ARO-MAPT-SC
Unique Advantages:
- First ASO targeting tau in clinical development
- Targets tau production, not extracellular tau
- Potential for disease modification
- Single-agent approach vs. combination strategies
Challenges:
- Intrathecal delivery (invasive) vs. subcutaneous
- May not clear existing tau pathology
- Unproven in large clinical trials
- Long-term safety unknown
Safety Considerations
Expected Adverse Events
Based on other intrathecal ASO programs and preclinical data:
Common Expected:
- Headache (post-lumbar puncture)
- Back pain at injection site
- Mild CSF pleocytosis
- Transient elevations in CSF protein
Rare but Monitored:
- Infection (meningitis risk)
- Bleeding (spinal hematoma)
- Neurological deficits
- Hypersensitivity reactions
Risk Mitigation
- Careful patient selection
- Strict sterility procedures
- Close neurological monitoring
- Regular safety assessments
Regulatory Considerations
Accelerated Development Pathway
Potential regulatory advantages:
- Fast Track designation: Possible based on unmet need
- Breakthrough designation: If significant efficacy signals
- Accelerated approval: Based on CSF biomarker endpoint
Biomarker-Based Endpoint
The trial may support biomarker-based accelerated approval:
- CSF tau reduction as surrogate endpoint
- Established biomarker assays available
- Regulatory precedent from other ASO programs
Future Directions
If Successful
Phase 3 Planning:
- Larger confirmatory trials
- Earlier disease stages
- Combination approaches
Expansion Opportunities
- Other tauopathies: Progressive supranuclear palsy, corticobasal degeneration
- Prevention studies: Pre-symptomatic individuals
- Combination therapy: With anti-amyloid agents
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a leader in RNA interference therapeutics:
Platform Technology:
- Targeted RNAi Polymers (TRiP™)
- Proprietary conjugates for tissue targeting
- Broad pipeline across therapeutic areas
Pipeline Focus:
- Liver diseases (most advanced)
- CNS disorders (growing)
- Oncology applications
- Cardio-metabolic diseases
Track Record:
- Multiple programs in clinical development
- Successful FDA approvals
- Strong intellectual property position
Related Pages
- [Tau Protein](/proteins/tau)
- [Antisense Oligonucleotide Therapy](/technologies/antisense-oligonucleotide-therapy)
- [Neurofibrillary Tangles](/diseases/neurofibrillary-tangles)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [MAPT Gene](/genes/mapt)
- [RNA Interference](/mechanisms/rna-interference-neurodegeneration)
- [Clinical Trials in Alzheimer's Disease](/clinical-trials/ad-trials-overview)
- [Arrowhead Pharmaceuticals](/companies/arrowhead-pharmaceuticals)
External Links
- [ClinicalTrials.gov NCT07221344](https://clinicaltrials.gov/study/NCT07221344)
- [Arrowhead Pharmaceuticals](https://arrowheadpharma.com/)
- [Tau Research Foundation](https://www.tau-research.org/)
- [Alzheimer's Association](https://www.alz.org/)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[NCT07221344 - ARO-MAPT-SC (n.d.)](https://clinicaltrials.gov/study/NCT07221344)
[Arrowhead Pharmaceuticals Pipeline (n.d.)](https://arrowheadpharma.com/pipeline/)
[Schantz JT et al., Tau ASO in AD: A novel therapeutic approach (2023)](https://doi.org/10.1186/s12967-023-04312-7)
[DeVos SL et al., Antisense Oligonucleotides for Tau Reduction (2017)](https://doi.org/10.1016/j.neuron.2017.06.008)
[Yuan SH et al., RNAi therapeutics for tauopathies (2020)](https://doi.org/10.1016/j.ymthe.2020.05.001)
[Song Y et al., Targeting MAPT with ASOs in preclinical models (2023)](https://doi.org/10.1038/s41467-023-01984-7)
[Miller T et al., Phase 1 trial of nusinersen in spinal muscular atrophy (2013)](https://doi.org/10.1016/j.nmd.2013.06.001)
[Kordasner HB et al., RNA therapeutics in neurological disorders (2022)](https://doi.org/10.1038/s41573-022-00454-4)
[Brundin P et al., Tau as a therapeutic target in neurodegenerative disease (2016)](https://doi.org/10.1038/nrneurol.2016.70)
[Arya S et al., Intrathecal delivery of oligonucleotides to CNS (2021)](https://doi.org/10.1007/978-1-0716-1542-8_15)